Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention

被引：0
|
作者：
Itziar Oyagüez
Carmen Suárez
José Luis López-Sendón
José Ramón González-Juanatey
Fernando de Andrés-Nogales
Jorge Suárez
Carlos Polanco
Javier Soto
机构：
[1] Pharmacoeconomics and Outcomes Research Iberia (PORIB),Internal Medicine Department
[2] Hospital La Princesa,Cardiology Department
[3] Hospital Universitario La Paz,Cardiology Department
[4] IdiPaz,undefined
[5] CIBER-CV,undefined
[6] Complejo Hospitalario Universitario de Compostela,undefined
[7] Bristol-Myers Squibb,undefined
[8] Pfizer,undefined
来源：
PharmacoEconomics - Open | 2020年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：485 / 497
页数：12
相关论文
共 50 条
  • [31] Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin
    Lee, Soyon
    Anglade, Moise W.
    Meng, Joy
    Hagstrom, Kelly
    Kluger, Jeffrey
    Coleman, Craig I.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2012, 5 (04): : 472 - 479
  • [32] Cost-effectiveness of apixaban against current standard of care (SoC) for stroke prevention in atrial fibrillation patients
    Dorian, P.
    Kongnakorn, T.
    Phatak, H.
    Rublee, D.
    Kuznik, A.
    Lanitis, T.
    Liu, L.
    Iloeje, U.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2012, 33 : 969 - 969
  • [33] Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
    Dorian, Paul
    Kongnakorn, Thitima
    Phatak, Hemant
    Rublee, Dale A.
    Kuznik, Andreas
    Lanitis, Tereza
    Liu, Larry Z.
    Iloeje, Uchenna
    Hernandez, Luis
    Lip, Gregory Y. H.
    EUROPEAN HEART JOURNAL, 2014, 35 (28) : 1897 - 1906
  • [34] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Athanasakis, Kostas
    Boubouchairopoulou, Nadia
    Karampli, Eleftheria
    Tarantilis, Filippos
    Savvari, Paraskevi
    Bilitou, Aikaterini
    Kyriopoulos, John
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (02) : 123 - 133
  • [35] Cost-effectiveness of apixaban versus other oral anticoagulants and aspirin for stroke prevention in atrial fibrillation in indian subcontinent
    Kulkarni, N.
    Taur, S.
    Tichy, E.
    Kongnakorn, T.
    Sharma, R.
    EUROPEAN HEART JOURNAL, 2022, 43
  • [36] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Kostas Athanasakis
    Nadia Boubouchairopoulou
    Eleftheria Karampli
    Filippos Tarantilis
    Paraskevi Savvari
    Aikaterini Bilitou
    John Kyriopoulos
    American Journal of Cardiovascular Drugs, 2017, 17 : 123 - 133
  • [37] COST-EFFECTIVENESS OF APIXABAN VERSUS OTHER NEW ORAL ANTICOAGULANTS AND WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN VENEZUELA
    Fernandez Avila, Y.
    Garcia, K. C.
    Garrido Lecca, S.
    Donato, B. M.
    Juarez-Garcia, A.
    VALUE IN HEALTH, 2015, 18 (07) : A829 - A829
  • [38] Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
    Walter, Evelyn
    Voit, Marco
    Eichhober, Gerald
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 265 - 275
  • [39] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN IRANIAN ATRIAL FIBRILLATION PATIENTS
    Keshavarz, K.
    Meshkini, Hashemi A.
    Nikfar, S.
    Ashkuh, M. S.
    Sanati, E.
    VALUE IN HEALTH, 2016, 19 (07) : A654 - A654
  • [40] Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
    Hersi, Ahmad S.
    Osenenko, Katherine M.
    Kherraf, Sid Ahmed
    Aziz, Ayman Abdel
    Sambrook, Robert Joseph
    ANNALS OF SAUDI MEDICINE, 2019, 39 (04) : 265 - 278
12345